Gut microbiome and tumor immunotherapy / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 432-436, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-989581
ABSTRACT
Neoplasms immunotherapy has made a major breakthrough in the clinical practice of refractory tumor. However, there are still individual differences in treatment results and drug resistance in clinical application. Gastrointestinal microbiome is gradually recognized as an immunoregulatory factor in recent years, and more and more studies have focused on its influences on the efficacy of tumor immunotherapy. Targeting gastrointestinal microbiota to improve the response of tumor patients to immunotherapy has potential clinical application value.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS